{"nctId":"NCT00922480","briefTitle":"Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients","startDateStruct":{"date":"2008-12"},"conditions":["Hypertension"],"count":506,"armGroups":[{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Losartan (Control)"]},{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Fimasartan"]}],"interventions":[{"name":"Fimasartan","otherNames":["A657-BR-CT"]},{"name":"Losartan (Control)","otherNames":["Cozar"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Mild to moderate essential hypertension : sitting diastolic blood pressure measured at Placebo visit and Baseline are 90\\~109mmHg inclusive and the difference between sitting diastolic blood pressures measured at Placebo visit and Baseline(Day0) is under 7mmHg.\n* Subjects who agree to participate in this sudy and give written informed consent\n* Subjects considered to understand the study, be cooperative, and able to be followed-up until the end of the study\n\nExclusion Criteria:\n\n* The sitting DBP is less than 89mmHg or more than 110mmHg or severe hypertensive patient with sitting systolic blood pressure over 200mmHg Patients with secondary hypertension\n* Patients with severe renal(Creatinine more 1.5 times than upper limit of normal), gastrointestinal, hematological or hepatic(AST, ALT more 2 twice more than upper limit of normal)disease etc. which might affect absorption, disposition, metabolism or excretion of the drug\n* Patients with postural hypotension\n* Patients with sever insulin dependent diabetes mellitus or uncontrolled diabetes mellitus(HbA1c\\>9%, regimen change of oral hypoglycemic agents within 12weeks, treated insulin before screening)\n* Patients with a history of myocardial infarction, severe coronary artery disease or clinically significant heart failure or valvular defect in last 6 months\n* Patients with consumptive disease, autoimmune disease, connective tissue disease\n* Patients with a history of type B or C hepatitis(include carrier)\n* Patients with HIV or hepatitis\n* Patients with clinically significant laboratory abnormality\n* Patients receiving any drugs known to affect blood pressure or medical treatments that can influence the blood pressure\n* Patients with allergy or contraindication to any angiotensin II receptor antagonists\n* Female of childbearing potential who does not undergo hysterectomy or is not post-menopausal\n* Patients judged to have a history of alcohol or drug abuse by the investigator\n* Patients participated other clinical trial 12 weeks before Screening Patients judged to be inappropriate for this study by the investigator with other reasons","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Diastolic Blood Pressure Change","description":"Value of DBP at 12 Weeks minus value of DBP at Baseline while in a sitting position","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.56","spread":"7.72"},{"groupId":"OG001","value":"-11.26","spread":"7.53"}]}]}]},{"type":"SECONDARY","title":"Diastolic Blood Pressure Change","description":"* Value of DBP at 4 Weeks minus value of DBP at Baseline while in a sitting position\n* Value of DBP at 8 Weeks minus value of DBP at Baseline while in a sitting position","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.73","spread":"6.56"},{"groupId":"OG001","value":"-8.22","spread":"7.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.01","spread":"7.16"},{"groupId":"OG001","value":"-11.01","spread":"7.63"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":250},"commonTop":["Headache","Dizziness","Nasopharyngitis","Upper respiratory tract infection","Dyspepsia"]}}}